Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P11487
UPID:
FGF3_HUMAN
Alternative names:
Heparin-binding growth factor 3; Proto-oncogene Int-2
Alternative UPACC:
P11487; Q0VG69
Background:
Fibroblast growth factor 3 (FGF3), also known as Heparin-binding growth factor 3 and Proto-oncogene Int-2, plays a pivotal role in embryonic development, cell proliferation, and differentiation. It is essential for normal ear development, highlighting its significance in auditory system formation.
Therapeutic significance:
FGF3 is linked to a unique autosomal recessive syndrome characterized by deafness with labyrinthine aplasia, microtia, and microdontia. This association underscores the protein's critical role in ear development and presents it as a potential target for therapeutic intervention in related congenital disorders.